KLP Kapitalforvaltning AS Acquires New Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

KLP Kapitalforvaltning AS bought a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The fund bought 48,388 shares of the biopharmaceutical company's stock, valued at approximately $34,468,000.

A number of other institutional investors have also recently made changes to their positions in REGN. FSA Wealth Management LLC acquired a new position in Regeneron Pharmaceuticals in the third quarter valued at approximately $26,000. OFI Invest Asset Management acquired a new position in shares of Regeneron Pharmaceuticals during the 4th quarter valued at $28,000. Rakuten Securities Inc. lifted its position in shares of Regeneron Pharmaceuticals by 62.5% during the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock valued at $28,000 after acquiring an additional 15 shares during the period. Avalon Trust Co bought a new position in Regeneron Pharmaceuticals during the fourth quarter worth $36,000. Finally, Private Wealth Management Group LLC grew its holdings in Regeneron Pharmaceuticals by 260.0% in the fourth quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company's stock worth $38,000 after purchasing an additional 39 shares during the period. Institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Price Performance

REGN traded down $4.31 during trading on Thursday, reaching $635.83. 811,470 shares of the company were exchanged, compared to its average volume of 640,846. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The company has a market cap of $69.51 billion, a price-to-earnings ratio of 16.61, a P/E/G ratio of 2.34 and a beta of 0.27. Regeneron Pharmaceuticals, Inc. has a 12-month low of $629.02 and a 12-month high of $1,211.20. The company's 50-day moving average is $685.91 and its two-hundred day moving average is $805.04.

Remove Ads

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating analysts' consensus estimates of $11.21 by $0.86. The company had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. Regeneron Pharmaceuticals's revenue was up 10.3% compared to the same quarter last year. During the same period last year, the business earned $11.86 earnings per share. Research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were paid a $0.88 dividend. The ex-dividend date was Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.55%. Regeneron Pharmaceuticals's dividend payout ratio is presently 2.30%.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. BMO Capital Markets dropped their price objective on shares of Regeneron Pharmaceuticals from $950.00 to $903.00 and set an "overweight" rating on the stock in a report on Tuesday, February 4th. Canaccord Genuity Group assumed coverage on Regeneron Pharmaceuticals in a research note on Tuesday, December 17th. They set a "hold" rating and a $165.00 price target on the stock. Wells Fargo & Company reduced their price objective on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an "overweight" rating for the company in a research note on Friday, January 10th. Leerink Partners raised Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and upped their target price for the stock from $762.00 to $834.00 in a research report on Wednesday, February 5th. Finally, Citigroup reduced their price target on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a "neutral" rating for the company in a research report on Tuesday, January 28th. One analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $973.13.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.